The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.
Pre-clinical pharmacology of AZD3965, a selective inhibitor of MCT1: DLBCL, NHL and Burkitt’s lymphoma anti-tumor activity
Open accessAbstract
// Nicola J. Curtis 1 , Lorraine Mooney 1 , Lorna Hopcroft 2 , Filippos Michopoulos 1 , Nichola Whalley 2 , Haihong Zhong 3 , Clare Murray 4,6 , Armelle Logie 1 , Mitchell Revill 1 , Kate F. Byth 5 , Amanda D. Benjamin 4 , Mike A. Firth 1 , Stephen Green 1 , Paul D. Smith 2 and Susan E. Critchlow 2 1 iMED Oncology, AstraZeneca, Alderley Park, Cheshire, UK 2 iMED Oncology, AstraZeneca, Cambridge, UK 3 MedImmune, One MedImmune Way, Gaithersburg, MD, USA 4 iMED DSM, AstraZeneca, Cambridge, UK 5 iMED Oncology, AstraZeneca, Gatehouse Park, Waltham, Massachusetts, MA, USA 6 C4X Discovery, Manchester, UK Correspondence to: Susan E. Critchlow, email: // Keywords : AZD3965, MCT1, metabolism, lactate Received : November 16, 2016 Accepted : May 15, 2017 Published : May 25, 2017 Abstract Tumors frequently display a glycolytic phenotype with increased flux through glycolysis and concomitant synthesis of lactate. To maintain glycolytic flux and prevent intracellular acidification, tumors efflux lactate via lactate transporters (MCT1-4). Inhibitors of lactate transport have the potential to inhibit glycolysis and tumor growth. We developed a small molecule inhibitor of MCT1 (AZD3965) and assessed its activity across a panel of cell lines. We explored its antitumor activity as monotherapy and in combination with doxorubicin or rituximab. AZD3965 is a potent inhibitor of MCT1 with activity against MCT2 but selectivity over MCT3 and MCT4. In vitro , AZD3965 inhibited the growth of a range of cell lines especially haematological cells. Inhibition of MCT1 by AZD3965 inhibited lactate efflux and resulted in accumulation of glycolytic intermediates. In vivo , AZD3965 caused lactate accumulation in the Raji Burkitt’s lymphoma model and significant tumor growth inhibition. Moreover, AZD3965 can be combined with doxorubicin or rituximab, components of the R-CHOP standard-of-care in DLBCL and Burkitt’s lymphoma. Finally, combining lactate transport inhibition by AZD3965 with GLS1 inhibition in vitro , enhanced cell growth inhibition and cell death compared to monotherapy treatment. The ability to combine AZD3965 with novel, and standard-of-care inhibitors offers novel combination opportunities in haematological cancers.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Otto Warburg's contributions to current concepts of cancer metabolism
Koppenol, W. H., Bounds, P. L., & Dang, C. V. (2011) · Nature Reviews Cancer · doi:10.1038/nrc3038 · Cited by 3,427
Activity of the Monocarboxylate Transporter 1 Inhibitor AZD3965 in Small Cell Lung Cancer
Polański, R., Hodgkinson, C. L., Fusi, A., Nonaka, D., Priest, L., Kelly, P., Trapani, F., Bishop, P. W., White, A., Critchlow, S. E., et al. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-2270 · Cited by 378
Self-citationMathupala, S. P., Parajuli, P., & Sloan, A. E. (2004) · Neurosurgery · doi:10.1227/01.neu.0000143034.62913.59 · Cited by 147
Cited by
Targeting cancer metabolism in the era of precision oncology
Stine, Z. E., Schug, Z. T., Salvino, J. M., & Dang, C. V. (2022) · Nature Reviews Drug Discovery · doi:10.1038/s41573-021-00339-6 · Cited by 1,189
Lactate in the Regulation of Tumor Microenvironment and Therapeutic Approaches
de la Cruz-López, K. G., Castro-Muñoz, L. J., Reyes-Hernández, D. O., García-Carrancá, A., & Manzo-Merino, J. (2019) · Frontiers in Oncology · doi:10.3389/fonc.2019.01143 · Cited by 940
Monocarboxylate transporters in cancer
Payen, V. L., Mina, E., Van Hée, V. F., Porporato, P. E., & Sonveaux, P. (2020) · Molecular Metabolism · doi:10.1016/j.molmet.2019.07.006 · Cited by 644
Metabolic heterogeneity confers differences in melanoma metastatic potential
Tasdogan, A., Faubert, B., Ramesh, V., Ubellacker, J. M., Shen, B., Solmonson, A., Murphy, M. M., Gu, Z., Gu, W., Martin, M., et al. (2020) · Nature · doi:10.1038/s41586-019-1847-2 · Cited by 509
Monocarboxylate Transporters (SLC16): Function, Regulation, and Role in Health and Disease
Felmlee, M. A., Jones, R. S., Rodriguez-Cruz, V., Follman, K. E., & Morris, M. E. (2020) · Pharmacological Reviews · doi:10.1124/pr.119.018762 · Cited by 467
Energy metabolism in health and diseases
Liu, H., Wang, S., Wang, J., Guo, X., Song, Y., Fu, K., Gao, Z., Liu, D., He, W., & Yang, L.-L. (2025) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-025-02141-x · Cited by 399
Lactate in the Tumor Microenvironment: An Essential Molecule in Cancer Progression and Treatment
Pérez-Tomás, R., & Pérez-Guillén, I. (2020) · Cancers · doi:10.3390/cancers12113244 · Cited by 385
Structural basis of human monocarboxylate transporter 1 inhibition by anti-cancer drug candidates
Wang, N., Jiang, X., Zhang, S., Zhu, A., Yuan, Y., Xu, H., Lei, J., & Yan, C. (2021) · Cell · doi:10.1016/j.cell.2020.11.043 · Cited by 340
Lactate: A key regulator of the immune response
Llibre, A., Kucuk, S., Gope, A., Certo, M., & Mauro, C. (2025) · Immunity · doi:10.1016/j.immuni.2025.02.008 · Cited by 283
Halford, S., Veal, G. J., Wedge, S. R., Payne, G. S., Bacon, C. M., Sloan, P., Dragoni, I., Heinzmann, K., Potter, S., Salisbury, B. M., et al. (2023) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-22-2263 · Cited by 276
Blaszczak, W., Williams, H., & Swietach, P. (2022) · British Journal of Cancer · doi:10.1038/s41416-022-01910-7 · Cited by 32
Metadata
- Authors
- Curtis, N. J., Mooney, L., Hopcroft, L., Michopoulos, F., Whalley, N., Zhong, H., Murray, C., Logie, A., Revill, M., Byth, K. F., Benjamin, A. D., Firth, M. A., Green, S., Smith, P. D., & Critchlow, S. E.
- Venue
- Oncotarget
- Publisher
- Impact Journals, LLC
- Published
- 2017-05-25
- Volume
- 8
- Issue
- 41
- Pages
- 69219-69236
- ISSN
- 1949-2553 (ISSN-L)
- OpenAlex
- W2620129301
- Cited by
- 165
- References
- 3
- FWCI
- 4.09
- Type
- journal article
- Language
- en
- Open access
- diamond
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.